
RCEL Stock Forecast & Price Target
RCEL Analyst Ratings
Bulls say
AVITA Medical is positioned for strong future growth with its innovative RECELL system, which has received approval in the US and international markets. The recent Cohealyx clinical data and portfolio expansion highlight the company's strategy of offering a comprehensive wound care platform aimed at improving healing outcomes. With a strong clinical foundation and management signaling a return to execution-led growth, AVITA Medical is expected to continue to see revenue growth and operational improvement in the future.
Bears say
AVITA Medical is grappling with several challenges, including significant reliance on a single product and a focus on the US market. Despite gaining product approval in multiple international markets, the company has not actively marketed in those territories, hindering potential revenue growth. Additionally, competition from other wound care solutions, regulatory and financial risks, and potential legal and intellectual property disputes may pose further challenges for the company.
This aggregate rating is based on analysts' research of AVITA Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
RCEL Analyst Forecast & Price Prediction
Start investing in RCEL
Order type
Buy in
Order amount
Est. shares
0 shares